Swiss pharma giant Roche presents positive data on eye disease drug

Roche: new data on the ophthalmic drug Vamikibart

Keystone-SDA

Basel-based pharmaceutical company Roche has presented new data on vamikibart, its experimental treatment for macular oedema associated with uveitis, a condition in which inflammation causes swelling in the macula.

Fuel prices rise again in Switzerland

Switzerland releases fuel reserves to ease shortage risks at Zurich airport

This content was published on

October 11, 2026 – 17:00

The data show that the treatment delivers sustained improvements in vision and reduces retinal swelling over a 52-week period.

Drug pricing

How a clash with Roche exposed cracks in Swiss drug pricing system

This content was published on

Sep 19, 2025

Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.

The results were presented on Saturday at the annual meeting of the American Academy of Ophthalmology in New Orleans, Roche said.

The data come from two identical Phase III trials. In both studies, a higher proportion of patients treated with vamikibart saw an improvement in vision compared with those in the control group. Around two-thirds of patients did not require any further injections after the initial treatment phase.

Big Pharma steps up race for AI-discovered drugs

This content was published on

May 30, 2024

AI is speeding up drug discovery but bringing an AI-discovered drug to market won’t happen overnight.

The drug has not yet been approved. The US Food and Drug Administration (FDA) has accepted Roche’s application and is expected to make a decision by July 2027. Applications have also been submitted in the European Union, China and Japan.

+ How we produce news in English

Translated from Italian, reviewed by an English Department journalist.

Source link